Please assess the completion status of the following clinical trial:

Trial Title: to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically confirmed diagnosis of primary solid tumor, and with pathologically or radiologically documented metastases~* Disease that is measurable or evaluable by RECIST 1.1 criteria (for Solid Tumors)~* Patient with metastatic cancer that are refractory to current standard/available therapies~Exclusion Criteria:~* brain metastases~* serious concurrent infection or nonmalignant illness that is uncontrolled~* uncontrolled intercurrent illness~* Immunocompromised~* significant traumatic injury within 3 weeks before Day 0~* History of hypersensitivity to any component of study drug

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 188Re-BMEDA-liposome (Type: EXPERIMENTAL): Stage I:~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose~Stage II:~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)~1. 0.42±0.04 mCi/kg~2. 0.63±0.06 mCi/kg~3. 0.84±0.08 mCi/kg~4. 1.05±0.11 mCi/kg~5. 1.26±0.13 mCi/kg~6. 1.47±0.15 mCi/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).